Caliper Life Sciences enters into settlement agreement with Shimadzu and its subsidiary Shimadzu Scientific Instruments

NewsGuard 100/100 Score
Mar 15 2010

Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announces that it has entered into a settlement agreement with Shimadzu Corporation and its wholly owned subsidiary Shimadzu Scientific Instruments, Inc., resolving a lawsuit filed by Caliper in the United States District Court for the Eastern District of Texas that claimed that Shimadzu's MultiNA microchip-based electrophoresis system infringed several U.S. patents relating to Caliper's microfluidic LabChip® technology.  Shimadzu denies infringement, but has discontinued sales of the MultiNA system in the United States.  The terms of the settlement were not disclosed.

Source:

Caliper Life Sciences, Inc.

Posted in:

Tags: , , , ,

Comments (0)

Suggested Reading

New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses
Feeling lonely? It may affect how your brain reacts to food, new research suggests
Unraveling the complexities of muscle repair in diabetes: A call for targeted research and therapies
ELRIG UK and SRG announce partnership to advance life science professionals in drug discovery
Researchers discover a safer and more efficient technique for testing new drugs
Expanding research and clinical options for children with cancer
AI-powered method predicts protein dynamics to accelerate drug discovery

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New research sheds light on how GLP-1 obesity drugs may change food cravings